Novavax NVAX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Development, tech transfer, launch, and sales milestone payments by Product | ||||||
| Adjuvant Products Thereafter | $210M— | —— | —— | —— | —— | |
| CIC Product-Related Development Milestones | $125M— | —— | —— | —— | —— | |
| CIC Product-Related Launch Milestones | $225M— | —— | —— | —— | —— | |
| First Four Adjuvant Products | $200M— | —— | —— | —— | —— | |
| Licensed COVID-19 products and royalty payments | $75M— | —— | —— | —— | —— | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| Canada | $0-100% | —— | $0— | $0— | $575.67M— | |
| Europe | $20.15M+149% | $3.37M+59.9% | $655K-63.9% | $3.63M+414% | $8.09M-91.1% | |
| Rest of the world | $23.28M-46.5% | $32.52M+76.4% | $13.01M+12.1% | $37.43M+84.6% | $43.49M+341% | |
| United States | $96.09M+144% | $111.24M+75.7% | $56.78M-20.1% | $198.18M-49.8% | $39.41M+713% | |
| Total long-lived assets by Geography | ||||||
| Europe | $6.49M+63.2% | $7.02M+70.3% | $3.67M— | $3.77M— | $3.97M— | |
| United States | $57.02M-80.1% | $60.68M-79.5% | $69.33M— | $278.92M— | $287.06M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Novavax break its business down?
- Novavax (NVAX) reports development, tech transfer, launch, and sales milestone payments by product across 5 parts — Adjuvant Products Thereafter, CIC Product-Related Development Milestones, CIC Product-Related Launch Milestones, First Four Adjuvant Products and Licensed COVID-19 products and royalty payments. Each is extracted from the segment footnotes and tracked over time.
- Where does Novavax's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Novavax's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
